DECEMBER 2, 2015
As published in the CEO/CFO Magazine
Interview conducted by: Lynn Fosse, Senior Editor, CEO/CFO Magazine, Published – November 30, 2015
CEO/CFO:
Ms. Zannes, would you tell us the overall vision at bioAffinity Technologies?
Ms. Zannes: bioAffinity Technologies is committed to continual scientific exploration, transparency and collaboration, and the development and commercialization of patient-friendly tests that accurately diagnose early stage cancer. The company has a strong international patent portfolio surrounding breakthrough technology for the early detection, monitoring and treatment of cancer. Our initial product will be an early-stage non-invasive test for lung cancer. We call our product CyPath®. We intend to develop a platform of products built around a very exciting technology.
